There is one clinical trial.
The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.
Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---